{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:35:52Z","timestamp":1783002952013,"version":"3.54.5"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Paraneoplastic cerebellar degeneration (PCD) is a heterogeneous group of neurologic syndromes associated with primary tumors. It is postulated that the immune system targets a tumor antigen that is also expressed endogenously in the nervous system. The majority of these patients are diagnosed with breast cancer or gynecological cancer, while it is exceedingly rare in lung squamous cell carcinoma (LUSC) patients. Here we reported a rare case of anti-Yo antibody-positive PCD in a patient with LUSC and got successfully treated via immunotherapy and oncological treatment. The patient\u2019s ataxia symptoms alleviated following the administered treatments, suggesting that early immunotherapeutic intervention may have potential value in mitigating neurological deterioration. Furthermore, active and timely management of the primary carcinoma is crucial.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1558867","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:26:11Z","timestamp":1742534771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case Report: Anti-Yo antibody mediated paraneoplastic cerebellar degeneration in a patient with squamous cell lung carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Chen-Hao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt031","article-title":"Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural Malignant mesothelioma","volume":"43","author":"Tanriverdi","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12883-022-02684-4","article-title":"Paraneoplastic cerebellar degeneration with anti-Yo antibodies and an associated submandibular gland tumor: a case report","volume":"22","author":"Imai","year":"2022","journal-title":"BMC Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg133","article-title":"Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients","volume":"126","author":"Shams\u2019ili","year":"2003","journal-title":"Brain"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1802-y","article-title":"Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration","volume":"135","author":"Small","year":"2018","journal-title":"Acta Neuropathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"8120689","DOI":"10.1155\/2017\/8120689","article-title":"Anti-Yo mediated paraneoplastic cerebellar degeneration associated with pseudobulbar affect in a patient with breast cancer","volume":"2017","author":"Martin","year":"2017","journal-title":"Case Rep Oncol Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51212","article-title":"Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration","volume":"7","author":"Herdlevaer","year":"2020","journal-title":"Ann Clin Trans neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2041-8","article-title":"Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies","volume":"66","author":"Raspotnig","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-04139-0","article-title":"Non-small cell lung cancer associated with late-onset Lambert-Eaton myasthenic syndrome and paraneoplastic cerebellar degeneration","volume":"41","author":"Cai","year":"2020","journal-title":"Neurol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1265797","article-title":"CDR2 and CDR2L line blot performance in PCA-1\/anti-Yo paraneoplastic autoimmunity","volume":"14","author":"Vorasoot","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066002","article-title":"CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration","volume":"8","author":"Eichler","year":"2013","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000963","article-title":"Paraneoplastic cerebellar degeneration: the importance of including CDR2L as a diagnostic marker","volume":"8","author":"Herdlev\u00e6r","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0001051516.09427.14","article-title":"Performance assessment of the new EUROLINE neurologic syndrome 15 Ag (IgG) for the determination of autoantibodies associated with neurological disorders","volume":"103","author":"Venkataraman","year":"2024","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.328","article-title":"Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review","volume":"3","author":"Venkatraman","year":"2016","journal-title":"Ann Clin Trans neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"iii, xi","DOI":"10.3310\/hta9290","article-title":"The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation","volume":"9","author":"Garside","year":"2005","journal-title":"Health Technol Assess"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2014.06.018","article-title":"Steroids and the blood-brain barrier: therapeutic implications","volume":"71","author":"Witt","year":"2014","journal-title":"Adv Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100649","DOI":"10.1016\/j.gore.2020.100649","article-title":"Potential effect of intravenous immunoglobulin against paraneoplastic cerebellar degeneration in progressive ovarian cancer","volume":"34","author":"Shibata","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021760","article-title":"Plasma exchange for treating anti-Yo-associated paraneoplastic cerebellar degeneration: Case report and literature review","volume":"99","author":"Hu","year":"2020","journal-title":"Medicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-020-01152-4","article-title":"Treatment of primary autoimmune cerebellar ataxia with mycophenolate","volume":"19","author":"Hadjivassiliou","year":"2020","journal-title":"Cerebellum (London England)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-007-9479-z","article-title":"Successful treatment of paraneoplastic cerebellar degeneration with rituximab","volume":"86","author":"Esposito","year":"2008","journal-title":"J Neurooncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1999.5553","article-title":"Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature","volume":"75","author":"Cao","year":"1999","journal-title":"Gynecol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.10.1931","article-title":"Paraneoplastic cerebellar degeneration. I. @ a clinical analysis of 55 anti-Yo antibody-positive patients","volume":"42","author":"Peterson","year":"1992","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos006","article-title":"Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo\u2013associated paraneoplastic cerebellar degeneration","volume":"14","author":"Rojas-Marcos","year":"2012","journal-title":"Neuro Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1558867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:26:16Z","timestamp":1742534776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1558867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2025.1558867"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1558867","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1558867"}}